宜明昂科-b(01541)再涨超13%,截至发稿,涨9.78%,报14.14港元,成交额8149.02万港元。消息面上,5月30日,宜明昂科宣布,公司将在2025年美国临床肿瘤学会(ASCO)年会上,以壁报形式公布替达派西普(timdarpacept,IMM01)联合阿扎胞苷针对初治的慢性粒-单核细胞白血病(CMML),以及联合替雷利珠单抗针对PD-1单抗失败的经典霍奇金淋巴瘤(cHL),珀维拉...
Source Link宜明昂科-b(01541)再涨超13%,截至发稿,涨9.78%,报14.14港元,成交额8149.02万港元。消息面上,5月30日,宜明昂科宣布,公司将在2025年美国临床肿瘤学会(ASCO)年会上,以壁报形式公布替达派西普(timdarpacept,IMM01)联合阿扎胞苷针对初治的慢性粒-单核细胞白血病(CMML),以及联合替雷利珠单抗针对PD-1单抗失败的经典霍奇金淋巴瘤(cHL),珀维拉...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.